Reunion Neuroscience

Reunion Neuroscience is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of mental health disorders through the advancement of next-generation psychedelic therapeutic solutions. Their primary focus is on developing innovative, patented, FDA-approved serotonergic psychedelic therapies for postpartum depression (PPD) and other challenging psychiatric conditions. They believe that psychedelics have the potential to provide safe, fast-acting, and durable treatment options for underserved mental health patients.

Reunion's lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. RE104 is designed to deliver a short duration psychedelic experience, making it more practical for clinical use than longer-acting psychedelics. They are actively investigating the use of RE104 in additional neuropsychiatric indications, including adjustment disorder in cancer patients, where there is a significant unmet need for faster-acting and more effective treatments.

Reunion Neuroscience is a clinical-stage biopharmaceutical company focused on developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders. Their mission is to push the boundaries of neuroscience to develop safe, fast-acting, short duration therapies that provide durable antidepressive effects for individuals whose needs are not met by current treatments, with a particular focus on postpartum depression. They envision a future where depression is not just managed, but cured.

Reunion Neuroscience promotes a culture of innovation and collaboration, focused on developing transformative therapies for mental health disorders. The company values bold science and is driven by a deep commitment to improving the lives of patients and families impacted by mental health challenges. They emphasize a team-oriented approach, comprised of industry entrepreneurs and scientific leaders with extensive experience in neuroscience pharmaceutical drug development, to advance its mission of creating a world where mental and emotional wellbeing is the baseline.